Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/11147/7148
Browse
5 results
Search Results
Book Part Greenmetric Journey of Izmir Institute of Technology: Agile Strategies Towards a Green Campus(Springer Science and Business Media Deutschland GmbH, 2026) Keskin, E.; Ökten, H.E.; Akpinar, İ.; Baran, Y.Recently, there has been growing attention towards sustainable approaches on university campuses through disseminating international evaluation systems, the UI GreenMetric World University Rankings (GM) attracting specific attention in particular. Türkiye is one of the countries where the number of participating universities in GM rises annually at a significant pace. Most of the large-scale university campuses in Türkiye were already built by the 1990s, which led these campuses to adapt themselves to higher standards for sustainability. In this context, Izmir Institute of Technology (IZTECH), a 33-year-old university, has applied for the GM with its Gülbahçe Campus since 2020. This paper aims to reveal IZTECH’s institutional agile sustainability strategy, energetic and collective processes, and good practices in the last five years while examining the outcomes through the GM’s evaluation of six assessment criteria. In this regard, the sustainability practices of IZTECH have been monitored since 2019 and compared to how the developments have improved the GM scores for the past 3 years. This study, focusing on the IZTECH campus through historical, social, educational, and technological perspectives, unveils the barriers between developing and implementing sustainability practices and examines the cohesion between GM scores and annual reports of campus activities for further projections towards a greener campus. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2026.Article Citation - Scopus: 2Flavonoids as Chemosensitizers in Leukemias(2025) Huseynova, N.; Çetinkaya, M.; Baran, Z.; Khalilov, R.; Mammadova, A.; Baran, Y.Flavonoids, a diverse group of natural compounds abundant in plants, fruits, and seeds, are not only responsible for the vibrant colors, fragrances, and flavors found in nature but also possess significant health benefits. Representing a secondary metabolite, these phytonutrients contribute to overall well-being. They have garnered considerable interest due to their diverse biological roles, encompassing antioxidant, anti-inflammatory, and anticancer properties. Flavonoids exert anticancer properties by interfering with different signaling pathways and molecules. Also, they have been demonstrated to exert chemosensitization features, where flavonoids may enhance the effectiveness of chemotherapy, and hold promise for improving cancer treatment outcomes as they have been discovered to make cancer cells more responsive to treatment. Understanding their influence on the regulation of cellular signaling provides a foundation for exploring their potential in combination with different chemotherapy agents and their possible single use for cancer treatment. Besides, they are believed to present a cost-effective approach to cancer therapeutics with possible implications for reducing the side effects of the current chemotherapy regimens, which can be a great therapeutic strategy for treating cancer types, including leukemia. This chapter explores potential approaches for creating anticancer treatments, focusing on leukemia, through integrating flavonoid nutraceuticals with traditional chemotherapy agents. © 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.Review Mesenchymal Stem Cells in Cancer Therapy(2025) Baran, Z.; Çetinkaya, M.; Baran, Y.The mesenchymal stem/stromal cells (MSCs) are multipotent cells that were initially discovered in the bone marrow in the late 1960s but have so far been discovered in almost all tissues of the body. The multipotent property of MSCs enables them to differentiate into various cell types and lineages, such as adipocytes, chondrocytes, and osteocytes. The immunomodulation capacity and tumor-targeting features of MSCs made their use crucial for cell-based therapies in cancer treatment, yet limited advancement could be observed in translational medicine prospects due to the need for more information regarding the controversial roles of MSCs in crosstalk tumors. In this review, we discuss the therapeutic potential of MSCs, the controversial roles played by MSCs in cancer progression, and the anticancer therapeutic strategies that are in association with MSCs. Finally, the clinical trials designed for the direct use of MSCs for cancer therapy or for their use in decreasing the side effects of other cancer therapies are also mentioned in this review to evaluate the current status of MSC-based cancer therapies. © 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.Article Citation - Scopus: 13Her2-Targeted, Degradable Core Cross-Linked Micelles for Specific and Dual Ph-Sensitive Dox Release(John Wiley and Sons Inc, 2022) Bayram, N.N.; Ulu, G.T.; Topuzoğulları, M.; Baran, Y.; Dinçer, İşoğlu, S.Here, a targeted, dual-pH responsive, and stable micelle nanocarrier is designed, which specifically selects an HER2 receptor on breast cancer cells. Intracellularly degradable and stabilized micelles are prepared by core cross-linking via reversible addition−fragmentation chain-transfer (RAFT) polymerization with an acid-sensitive cross-linker followed by the conjugation of maleimide–doxorubicin to the pyridyl disulfide-modified micelles. Multifunctional nanocarriers are obtained by coupling HER2-specific peptide. Formation of micelles, addition of peptide and doxorubicin (DOX) are confirmed structurally by spectroscopical techniques. Size and morphological characterization are performed by Zetasizer and transmission electron microscope (TEM). For the physicochemical verification of the synergistic acid-triggered degradation induced by acetal and hydrazone bond degradation, Infrared spectroscopy and particle size measurements are used. Drug release studies show that DOX release is accelerated at acidic pH. DOX-conjugated HER2-specific peptide-carrying nanocarriers significantly enhance cytotoxicity toward SKBR-3 cells. More importantly, no selectivity toward MCF-10A cells is observed compared to HER2(+) SKBR-3 cells. Formulations cause apoptosis depending on Bax and Caspase-3 and cell cycle arrest in G2 phase. This study shows a novel system for HER2-targeted therapy of breast cancer with a multifunctional nanocarrier, which has higher stability, dual pH-sensitivity, selectivity, and it can be an efficient way of targeted anticancer drug delivery. © 2021 Wiley-VCH GmbHEditorial